AnaptysBio has reported that the ARISE-AD trial of its investigational B and T lymphocyte attenuator (BTLA) agonist, ANB032, ...

AnaptysBio is dropping its atopic dermatitis (AD) drug candidate after the compound failed to reduce eczema area and itch ...

As previously reported, Guggenheim downgraded Q32 Bio (QTTB) to Neutral from Buy and removed the firm’s prior price target following the ...

Dupilumab treatment improves signs and symptoms of atopic dermatitis (AD) in young children, according to a study published ...

Brittany Lancellotti, DVM, DACVD, offered ways veterinarians can help reduce caregiver burden in clients in an interview at the 2024 Fetch Long Beach conference ...

In allergen-driven models of atopic dermatitis, subcutaneous (SQ) administration of ‘1104 demonstrated comparable performance to intravenous administration (IV)In multiple preclinical models evaluated ...

Brittany Lancellotti, DVM, DACVD, talks about available treatment options for flea allergies, environmental allergies, and ...

Jojoba is a seed oil made from a desert shrub. It’s used to restore hair to its optimal state. Learn how to apply jojoba oil ...

Research at National Jewish Health and other institutions has shown that the biologic dupilumab improves signs and symptoms ...

The prevalence of Meniere disease is higher in people with atopic dermatitis (AD), according to a study published online Nov.

H.C. Wainwright downgraded AnaptysBio (ANAB) to Neutral from Buy with a price target of $19, down from $52, after the company announced topline ...

Atopic dermatitis was associated with a significantly increased bipolar disorder risk among a large population-based cohort in the US.